報價延遲最少15分鐘:2025/08/26 05:36 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.42
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.02/-2.47
|
|
企業價值
387.16M
|
| 資產負債 |
|
每股賬面淨值
2.93
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/26 05:36 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
